[{"orgOrder":0,"company":"DTx Pharma","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"DTx Pharma Completes $100M Series B Financing to Advance its FALCON\u2122 Platform and Pipeline of RNA Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$500.0 million","newsHeadline":"DTx Pharma Announces Acquisition by Novartis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by DTx Pharma
Through the acquisition, Novartis will accelerate the development of DTx-1252, a novel, potential first-in-class, FALCON siRNA candidate targeting PMP22, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
DTx-1252 is a potential first-in-class FALCON™ siRNA therapeutic for treatment of CMT1A. By repressing PMP22, DTx-1252 reverses CMT1A in a mouse model that faithfully recapitulates the genetic and clinical manifestations of the disease.
Proceeds from the financing will be used to advance DTx’s pipeline utilizing its novel FALCON (Fatty Acid Ligand Conjugated OligoNucleotide) platform technology.
The award, along with prior and pending grants, will enable DTx to expand the application of its lipid conjugate technology for the delivery of oligonucleotides as potential treatment for neurodegenerative diseases.